BioSante Pharmaceuticals, Inc. Announces Receipt of LibiGel(R) Special Protocol Assessment (SPA) Conference Call Today
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will host a conference call today, Tuesday, January 29, 2008 at 11:00 a.m. ET to discuss the LibiGel (testosterone gel) SPA received from the U.S. Food and Drug Administration (FDA) for the development of LibiGel in the treatment of female sexual dysfunction.